Back to Dashboard
BCRX · Healthcare

Biocryst Pharmaceuticals Inc

USA Healthcare Filing: 2026-06-30
33/100
Smart-money confidence1 of 3 sources positive
Below average interest

No standout activity across the feeds we track.

What this band has actually done: stocks scoring 25–45 beat the S&P 500 over the next three months 45.3% of the time, across 39,662 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this

Hedge funds
44
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$2.1B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NasdaqGS
About BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in…

Who's behind the signal
Every informed buyer we can see on BCRX, across all three feeds.
Hedge funds · 9
Point72 (Steve Cohen) New position
Renaissance Technologies Increased +226%
Citadel Advisors Increased +73%
AQR Capital Management Increased +403%
+3 more in the full breakdown below ↓
Congress · 2
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 5 on record
Disclosures from 2022-08-11 to 2026-07-10
Trade date Member Chamber Action Amount
2026-07-10 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2025-11-13 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2023-10-16 Josh Gottheimer · D-NJ House Bought $1,001 - $15,000
2023-09-15 Josh Gottheimer · D-NJ House Sold $1,001 - $15,000
2022-08-11 Josh Gottheimer · D-NJ House Bought $1,001 - $15,000
Not a model pick — but on our radar. BIOCRYST PHARMACEUTICALS INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
2
New positions
5
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to BIOCRYST PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BIOCRYST PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime